JPMorgan discloses dealings in Kangji Medical derivatives amid privatization push

On November 10, 2025, J.P. Morgan Securities PLC, identified as a Class (5) associate connected with the offeror, disclosed multiple dealings in Kangji Medical Holdings Limited derivatives. These transactions, made for its own account, involved closing out various derivative contracts. The largest of these involved 2,500 units with a maturity date of December 29, 2025, at a reference price of $9.1022, resulting in $22,755.50 received and a resultant balance of 9,200,843 units.

Additional transactions included closing out 1,500 units maturing on February 10, 2026, at $9.1519, yielding $13,727.85 and a balance of 9,203,343 units. Two other derivative contracts for 1,000 and 500 units, both maturing on December 29, 2025, were closed at $9.1022, resulting in $9,102.20 and $4,551.10 respectively, contributing to balances of 9,199,843 and 9,199,343 units.

Furthermore, a significant closing out of a derivative contract for 423,000 units was disclosed, maturing on September 2, 2027, at a reference price of $9.1051. This transaction generated $3,851,457.30, leaving a resultant balance of 8,776,343 units. J.P. Morgan Securities PLC is ultimately owned by JPMorgan Chase & Co.